Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc.

Biotechnology • Healthcare • EmeryVille, CA, United States • ESLAW (NCM)

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

510 318 9098 5858 Horton Street, EmeryVille, CA 94608, United States

Stock Performance (90 Days)

Data through Dec 11, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Estrella Immunopharma stock soars after 100% complete response rate in trial - Investing.com
Investing.com • Nov 3
Estrella Immunopharma offers up to 2.5 mln shares for resale by selling stockholders - marketscreener.com
marketscreener.com • Dec 22
Estrella Immunopharma shares gain as CD19 cancer therapy progresses into phase II - MSN
MSN • Dec 4
Estrella (NASDAQ: ESLA) passes DSMB; EB103 high-dose cohort reports 100% CR - Stock Titan
Stock Titan • Dec 4
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients - Business Wire
Business Wire • Nov 3

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Estrella Immunopharma, Inc. had layoffs?
No layoff events have been recorded for Estrella Immunopharma, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
What industry is Estrella Immunopharma, Inc. in?
Estrella Immunopharma, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Estrella Immunopharma, Inc. a publicly traded company?
Yes, Estrella Immunopharma, Inc. is publicly traded under the ticker symbol ESLAW on the NCM.
Where is Estrella Immunopharma, Inc. headquartered?
Estrella Immunopharma, Inc. is headquartered in EmeryVille, CA, United States at 5858 Horton Street, EmeryVille, CA 94608, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.